Share information

Investment highlights

1. Significant unmet medical need in mild-to-moderate psoriasis
   • Large target market of more than 18m patients across the US and the EU-5 alone
   • Significant unmet medical need for new treatment options and a patient population with a high degree of disease-involvement
2. Strong scientific rationale and promising clinical effect in mild-to-moderate psoriasis
   • Efficacy signals demonstrated in a completed randomized controlled clinical trial, showing sustained and increased effects over time
   • Unencumbered asset with worldwide rights retained
   • International clinical phase IIb trial with 519 patients, the HeROPA-study, fully recruited and progressing according to plan
3. Cash generative and growing nutraceutical business
   • Strong foundation secured through self-sustaining nutraceutical business that supports pharmaceutical development
   • Revenue of NOK 33,8m in 2023, with significant growth potential the years to come based on launch of new products and growing presence in large markets
4. Proprietary technology platform with control over value chain
   • Experienced R&D-team and full control of the value chain
   • Protected by a comprehensive portfolio of patents, technological know-how, and confirmed freedom to operate
5. Robust ESG-footprint
   • Sustainable end-product based on immature roe, a by-product of herring capture
   • Strategically situated to ensure sustainable access to immature roe
6. Expert management team
   • Highly skilled team of talents with diverse and highly relevant background, and an average of over 20 years of relevant industry experience

Major shareholders

We update the list of major shareholders on a quarterly basis.

Information Document

The document (the “Information Document”) has been prepared by Arctic Bioscience AS (the “Company”) solely for the use in connection with the admission to trading of all of its shares on Euronext Growth. First day of trading in the Company’s shares on Euronext Growth is expected 24 February 2021. DNB Markets, a part of DNB Bank ASA and ABG Sundal Collier ASA has acted as financial advisors and Wiersholm has acted as legal advisor to the Company in connection with the admission to trading of the Shares on Euronext Growth.

Dividend policy

Arctic Bioscience is currently in a growth phase and will seek to deploy available capital towards growth initiatives. Beyond the growth phase, it is the Company's ambition to pay dividends to shareholders as soon as it considers itself to be in a position to do so and when it is considered to be in the general interest of the shareholders.